

Myeloma Service- Trial guide

	Bone disease	Renal Impairment	Transplant eligible	Transplant ineligible	Amyloid
Newly Diagnosed		OPTIMAL eGFR < 30ml/min Bendamustin/dex + Thalidomide vs Bortezomib	CARDAMON CCD induction, foll by ASCT vs CFZ Maintenance MUK 9 High risk Myeloma		
Relapsed	MM XII – ITD reinduction followed by second ASCT				Tourmaline (Oral proteasome inhibitor) Ixa/dex vs Len/ Dex. For PI naïve patients
	MUK7 Pom/Cyclo/ Dex vs Pom/ Dex (Len exposed patients only) MUK8 Ixazomib/ Cyclo/ Dex vs Cyclo/ Dex (Len & Bortezomib exposed patients)				
Relapsed/ Refractory MM	C92480 + Dex trial Lenalidomide and Bortezomib exposed patients		D2 / FUSION trial Daratumumab + Durvalumab for RRMM Len & Bortezomib exposed pts		

OPEN **COMING SOON** **EPH = Early Phase Hub**